Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Recursion Pharmaceuticals › Many investors seek to capitalize on the rapidly growing artificial intelligence (AI) industry.

Governments are racing to build AI smarter than humans. Experts warn the first to reach AGI could reshape global ...

As concerns grow about AI chatbots leading users into delusional spirals, prominent spiritual influencers are capitalizing on ...

New research explores how prolonged AI interactions can, at least for some users, start to blur the lines between reality and fantasy. Simple interventions could prevent tragic outcomes.

Vincent Boucher, widely recognized as one of the earliest pioneers in AGI (artificial general intelligence), today announced ...

Tech pioneers Dave Copps and Taylor Shead explain how artificial intelligence is transforming the way companies operate, ...

Vincent Boucher today announced the evolution of (AGI Alpha), a blockchain-native AGI-First platform designed to redefine how intelligence is orchestrated, shared, and monetized globally ...

Absci's AI-driven drug discovery platform, its potential, challenges, and strategic partnerships. Read here for an investment analysis of ABSI stock.